GlassScriptPhysician profile
Jason Asher Damsker
NPI 1427068683
$11,790.15
in general payments reported to CMS, 2019-2025
52 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,684 · 2020: $1,774 · 2021: $11.92 · 2022: $35.54 · 2023: $734 · 2024: $5,685 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,426 · Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,425.50 |
| Food and Beverage | $2,859.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,014.95 | 2019-2024 | Alunbrig, Ninlaro |
| Genzyme Corporation | $1,784.01 | 2020-2024 | |
| Rigel Pharmaceuticals, INC. | $1,338.24 | 2019-2023 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $1,054.41 | 2019-2024 | Enhertu, Injectafer |
| Genentech USA, INC. | $950.86 | 2019-2024 | Polivy, Tecentriq |
| Janssen Biotech, INC. | $481.83 | 2019-2025 | Erleada, Talvey, Darzalex |
| Pfizer INC. | $355.52 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $343.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.22 | 2019-2025 | Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $323.47 | 2019-2024 | Opdivo, Krazati, Eliquis |
| Pharmacosmos Therapeutics INC. | $234.35 | 2024-2025 | Monoferric |
| Merck Sharp & Dohme LLC | $212.60 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $179.44 | 2019-2024 | Pemazyre, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $147.78 | 2019-2024 | Libtayo |
| Glaxosmithkline, LLC. | $139.26 | 2023-2025 | Jemperli, Zejula, Ojjaara |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $136.56 | 2019 | |
| Astellas Pharma US INC | $125.45 | 2019-2025 | Xtandi, Vyloy |
| Celgene Corporation | $118.78 | 2019-2024 | Reblozyl |
| Gilead Sciences, INC. | $104.52 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $102.15 | 2020-2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $84.05 | 2019-2023 | Imbruvica |
| Amgen INC. | $79.92 | 2019-2020 | |
| Foundation Medicine, INC. | $70.14 | 2019-2022 | |
| Mirati Therapeutics, INC. | $69.77 | 2023-2024 | Krazati |
| Abbvie INC. | $64.99 | 2019-2024 | |
| Morphosys, US INC. | $64.49 | 2023-2024 | Monjuvi |
| Lilly USA, LLC | $63.96 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Array Biopharma INC | $55.21 | 2024 | Lorbrena, Braftovi, Mektovi |
| Genmab U.S., INC. | $53.79 | 2024 | Epkinly, Tivdak |
| Progenics Pharmaceuticals, INC. | $52.45 | 2024 | |
| Eisai INC. | $48.90 | 2023 | |
| Caris Mpi, INC. | $48.51 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $43.27 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $32.89 | 2019 | |
| Emmaus Medical, INC. | $32.27 | 2019-2020 | |
| Lifenet Health | $27.65 | 2025 | Theragenesis Wound Matrix |
| Ipsen Biopharmaceuticals, INC | $24.77 | 2025 | Somatuline Depot, Onivyde |
| Seagen INC. | $24.52 | 2023 | Adcetris |
| Servier Pharmaceuticals LLC | $24.19 | 2024 | |
| Dova Pharmaceuticals | $22.46 | 2019 | |
| Apellis Pharmaceuticals, INC. | $22.45 | 2024 | Empaveli |
| Clovis Oncology, INC. | $22.26 | 2019 | |
| Stemline Therapeutics INC. | $21.61 | 2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $20.08 | 2019 | |
| Aurobindo Pharma USA, INC. | $19.19 | 2020 | |
| Sobi, INC | $19.10 | 2023 | |
| Secura Bio, INC. | $18.99 | 2019 | |
| Fortovia Therapeutics, INC. | $18.72 | 2019 | |
| Advanced Accelerator Applications | $18.43 | 2019 | |
| Tesaro, INC. | $17.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Damsker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.